research Abietic Acid from Resina Pini of Pinus Species as a Testosterone 5.ALPHA.-Reductase Inhibitor
Abietic acid from pine resin can effectively inhibit testosterone 5α-reductase.
Search
for
Sort by
Research
150-180 / 1000+ results research Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
research Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
research Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
research Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
research Re: A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Post-Finasteride Syndrome
research The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness
research Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women
research Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Review: Adding α1-blockers to 5α-reductase inhibitors improves lower urinary tract symptoms in men
Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
research DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
research The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
research Effects of Finasteride (MK-906), a 5α-Reductase Inhibitor, on Circulating Androgens in Male Volunteers*
Finasteride safely lowers DHT levels without affecting testosterone.
research Effect of Testosterone Supplementation With and Without a Dual 5α-Reductase Inhibitor on Fat-Free Mass in Men With Suppressed Testosterone Production
Testosterone's muscle-building effects do not require its conversion to DHT.
research Association of Suicidality and Depression With 5α-Reductase Inhibitors
Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
research Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials
5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
research Nipple Differentiation in Fetal Male Rats Treated with an Inhibitor of the Enzyme 5α-Reductase: Definition of a Selective Role for Dihydrotestosterone*
Blocking a specific enzyme in male rat fetuses leads to the development of nipples and feminized genitalia.
research Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride
Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
research Curcuma aeruginosa, a novel botanically derived 5α-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebo-controlled study
Curcuma aeruginosa extract combined with minoxidil effectively treats male-pattern baldness.
research 12 Treatment of hirsutism with 5α-reductase inhibitors
New compounds may soon be tested to treat excessive hair growth in women.
research Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
research 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives
Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
research 5α-reductase inhibitors impact prognosis of urothelial carcinoma
5α-reductase inhibitors may lower the risk of death from bladder cancer.
research 5α‐Reductase inhibitors and prostatic disease
5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.